血脂康胶囊治疗高胆固醇血症的经济学评价

目的评价中药血脂康治疗高胆固醇血症的经济效果.方法将79例高胆固醇血症患者随机分为两组,治疗组37例,对照组42例,用药物经济学方法进行成本-效果分析.结果TC每下降1mmol/L,血脂康和普伐他汀的费用分别是473.02、642.12元;TG每下降1mmol/L,费用分别是2003.38、6788.21元;LDL-C每下降1mmol/L,费用分别是490.03、693.68元;在血脂康疗效的基础上增加一个效果单位,费用分别是100.00、338.84元.相比而言,血脂康成本-效果低于普伐他汀.结论药物经济学研究可以弥补临床药物疗效观察研究的不足,在指导合理用药、减轻患者经济负担、提高社会经济效益和指导新药开发方面具有重要作用.

Application of Cost-Effectiveness Analysis in Xuezhikang and Pravastatin for the Treatment of Hypercholesterolemia

Objective To evaluate the economic effectiveness in the treatment of hypercholesterolemia by Xuezhikang and pravastatin differently. Methods 79 patients with hypercholesterolemia were randomly divided into two groups. Using pharmacoeconomical cost-effectiveness analysis, Xuezhikang and pravastatin were compared for the treatment of hypercholesterolemia. Results The cost of Xuezhikang and pravastatin lowering per l mmol/L TC were RMB 473.02 yuans and 642.12 yuans, lowering per l mmol/L TG were RMB 2003.38 yuans and 6788.21 yuans, lowering per l mmol/L LDL-C were RMB 490.3 yuans and 693.68 yuans. Xuezhikang was better than pravastatin in lasting treatment for hypercholesterolemia. Conclusion The results show that pharmacoeconomics is very important in guiding rational drug use and increasing economic effectiveness.